by marcbacon | Aug 15, 2022
We Need a New Prozac: The Demand for Brain Drug Innovation Aug. 15, 2022 · The Pharma Letter An Expert View from Emer Leahy, chief executive, and Dani Brunner, chief innovation officer, of PsychoGenics, on the challenges involved in tackling mental disorders. One...
by marcbacon | Aug 14, 2022
By Yitzi Weiner · Aug. 14, 2022 · Medium Delegate and accept imperfection — I find myself getting anxious when I take on too much and realize that I must delegate better and learn to let go more. While this this does not always come easily, letting go does feel...
by marcbacon | Aug 5, 2022
By Brian Buntz | August 1, 2022 [image courtesy of Pixabay] The late 1980s and the 1990s were something of a gold rush for pharmaceutical companies focused on CNS drug development — especially those developing psychiatric drugs. In 1988, Eli Lilly introduced the...
by marcbacon | Mar 15, 2022
Can you give an overview of how business has evolved for PsychoGenics over the past year? There are two sides to PsychoGenics; a preclinical CNS focused CRO and drug discovery. On the CRO side, PsychoGenics experienced significant growth with our service...
